Océanie · Actualité · The Mercury

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

Publié par The Mercury · Australie il y a 12 h

Alterity Therapeutics has presented additional analyses of its Phase 2 trial showing the 50mg twice-daily dose of its lead drug candidate ATH434 slowed functional ...

Lire l'article complet sur The Mercury Connectez-vous pour sauvegarder

MediaNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.themercury.com.au)

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

À lire aussi

Major parties all flag big cuts to immigration numbers

Behind the scenes at Perth’s most controversial expo

Taylor would hold net overseas migration at annual 100,000 for two years in plan hitting students, refugees

A family's heartbreak after watching a loved one die from Australia's no.1 killer

Aula Energy plans 1.8 GWh battery to ‘optimise’ 330 MW solar farm

Judith Lucy announces breast cancer diagnosis: ‘I’m in shock, but I’m OK’

Alterity’s biomarker-adjusted Phase 2 analysis shows ~52pc slowing of MSA decline

Partager

À lire aussi

Major parties all flag big cuts to immigration numbers

Behind the scenes at Perth’s most controversial expo

Taylor would hold net overseas migration at annual 100,000 for two years in plan hitting students, refugees

A family's heartbreak after watching a loved one die from Australia's no.1 killer

Aula Energy plans 1.8 GWh battery to ‘optimise’ 330 MW solar farm

Judith Lucy announces breast cancer diagnosis: ‘I’m in shock, but I’m OK’